Skip to main content
. 2020 Jul 9;9(7):1655. doi: 10.3390/cells9071655

Figure 8.

Figure 8

Regorafenib significantly downregulates tau phosphorylation at T212 and S214 and GSK3β activity in 5x FAD mice. (A–T) 5x FAD mice were injected with regorafenib (30 mg/kg, i.p.) or vehicle (2% DMSO + 30% PEG + 5% Tween 80) daily for two weeks, and immunohistochemistry was performed with anti-AT100 (A–E, n = 4 mice/group), anti-p-GSK3β (Y216) (F–J, n = 4 mice/group), anti-p-CDK5 (K–O, Veh, n = 3 mice/group; regorafenib, n= 4 mice/group), or anti-DYRK1A antibodies (P–T, n = 4 mice/group). * p < 0.05, ** p < 0.01, *** p < 0.001.